Research progress of chimeric antigen receptor T cell and T cell antigen coupler modified T cell technology
10.13200/j.cnki.cjb.003865
- VernacularTitle:嵌合抗原受体T细胞及T细胞抗原耦合器修饰T细胞技术的研究进展
- Author:
LU Tingting
- Publication Type:Journal Article
- Keywords:
T cell antigen coupler;
Cell modification;
Cancer;
Immunotherapy;
Chimeric antigen receptor T cell(CAR-T)
- From:
Chinese Journal of Biologicals
2023;36(4):495-
- CountryChina
- Language:Chinese
-
Abstract:
At present,malignant tumor has become one of the public problems that seriously threaten human health. In addition to surgery,radiotherapy,chemotherapy,targeted therapy and other methods,with the development of molecular biology,immunotherapy has also developed rapidly,becoming an emerging method of cancer treatment. The most commonly used immune cells in clinical treatment are DC,NK,CIK,CTL and chimeric antigen receptor T cell(CAR-T). Among them,CAR-T technology is the initial technology for global research,while due to its off-target,neurotoxicity,transfection vector defects and other problems,it also has certain limitations in clinical application. T cell antigen coupler modified T cell(TAC-T)technology is a new technology developed on the basis of CAR-T,which uses natural T cell receptor(TCR)to modify T cells and retarget the antigen of cancer cells. In this paper,the research status of CAR-T technology and the research progress of TAC-T technology are reviewed in order to provide reference for further study on the mechanism of TAC-T technology and its safety of clinical application.
